Dengue and zika seropositivity, burden, endemicity, and cocirculation antibodies in Nigeria.


Journal

Annals of medicine
ISSN: 1365-2060
Titre abrégé: Ann Med
Pays: England
ID NLM: 8906388

Informations de publication

Date de publication:
12 2023
Historique:
medline: 21 4 2023
pubmed: 19 4 2023
entrez: 19 04 2023
Statut: ppublish

Résumé

Mosquito-borne infections are of global health concern because of their rapid spread and upsurge, which creates a risk for coinfections. DENV and ZIKV are transmitted by We conducted a cross-sectional study of 871 participants from three regions of Nigeria. All serum samples were analysed using malaria RDT and the immunoblot molecular diagnostic assay recomLine Tropical Fever for the presence of arboviral antibody serological marker IgG (Mikrogen Diagnostik, Neuried, Germany) with DENV and ZIKV Nonstructural protein 1 (NS 1), DENV and ZIKV Equad (variant of the envelope protein with designated mutations to increase specificity), according to the manufacturer's instructions. The overall IgG antibody seropositivity against DENV-flavivirus was 44.7% (389/871); 95% CI (41.41-47.99), while ZIKV-flavivirus was 19.2% (167/871); 95% CI (0.16-0.21), and DENV-ZIKV-flavivirus cocirculation antibody seropositivity was 6.2%5 (54/871); 95% CI (0.6-0.7) in the three study regions of Nigeria. The study cohort presented similar clinical signs and symptoms of flaviviruses (DENV and ZIKV) in all three study regions. This study highlighted an unexpectedly high antibody seropositivity, burden, hidden endemicity, and regional spread of mono- and co-circulating flaviviruses (DENV and ZIKV) in Nigeria.Key messagesDengue flavivirus sero-cross-reactivity drives antibody-dependent enhancement of ZIKV infection.Both viruses share common hosts (humans) and vectors (primarily Aedes aegypti), and are thus influenced by similar biological, ecological, and economic factors, resulting in epidemiological synergy.Additionally, the actual burden in epidemic and interepidemic periods is grossly or chronically unknown and underreported. Despite this trend and the potential public health threat, there are no reliable data, and little is known about these arboviral co-circulation infections.

Identifiants

pubmed: 37074313
doi: 10.1080/07853890.2023.2175903
pmc: PMC9970210
doi:

Substances chimiques

Antibodies, Viral 0
Immunoglobulin G 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

652-662

Subventions

Organisme : World Health Organization
ID : 001
Pays : International

Références

Pathogens. 2022 Jul 04;11(7):
pubmed: 35890007
Bull Math Biol. 2020 Jan 14;82(1):13
pubmed: 31933003
J R Soc Interface. 2013 Jul 03;10(86):20130414
pubmed: 23825116
PLoS Negl Trop Dis. 2016 Dec 7;10(12):e0005194
pubmed: 27926925
BMC Infect Dis. 2018 Jan 30;18(1):61
pubmed: 29382300
Virus Res. 2017 Feb 15;230:7-12
pubmed: 28027928
Medicine (Baltimore). 2016 Mar;95(12):e3201
pubmed: 27015222
Immun Inflamm Dis. 2018 Jun;6(2):194-206
pubmed: 29282904
Clin Infect Dis. 2017 Jan 1;64(1):72-75
pubmed: 27694479
J Clin Virol. 2018 Aug;105:35-40
pubmed: 29885620
Virus Res. 2014 Oct 13;191:59-61
pubmed: 25087878
J Infect Public Health. 2019 Mar - Apr;12(2):178-181
pubmed: 30301701
Nucleic Acids Res. 2017 Jan 4;45(D1):D482-D490
pubmed: 27899678
Clin Infect Dis. 2016 Dec 15;63(12):1584-1590
pubmed: 27578819
J Infect Dis. 2018 Jul 13;218(4):563-571
pubmed: 29659904
PLoS Negl Trop Dis. 2012;6(2):e1472
pubmed: 22363822
Int J Environ Res Public Health. 2022 Jul 22;19(15):
pubmed: 35897268
Infect Chemother. 2021 Jun;53(2):284-299
pubmed: 34216122
Emerg Infect Dis. 2011 Aug;17(8):1349-54
pubmed: 21801609
Sci Rep. 2022 Oct 14;12(1):17225
pubmed: 36241869
HIV AIDS (Auckl). 2017 Jun 30;9:145-151
pubmed: 28721101
Afr Health Sci. 2019 Jun;19(2):2000-2007
pubmed: 31656483
Emerg Infect Dis. 2015 Feb;21(2):381-2
pubmed: 25625687
Trans R Soc Trop Med Hyg. 1954 Mar;48(2):139-45
pubmed: 13157159
Trop Doct. 2020 Jan;50(1):22-30
pubmed: 31462185

Auteurs

Peter Asaga Mac (P)

Institute of Virologie, Universitatsklinikum, Freiburg, Freiburg, Germany.

Markos Tadele (M)

Ethiopian Institute of Agricultural Research/EIAR, Addis Ababa, Ethiopia.

Philomena E Airiohuodion (PE)

Special Programme for Research & Training in Tropical Diseases (TDR), World Health Organization, Switzerland.

Thilini Nisansala (T)

Faculty of Veterinary Medicine, Universiti Malaysia Kelantan, Kelantan, Malaysia.

Shaistha Zubair (S)

Faculty of Medicine, University of Maldives, Maldives.

Jude Aigohbahi (J)

Sanofi-Aventis Deutschland GmbH, Clinical trials, Frankfurt, Germany.

Chukwuma Anyaike (C)

Federal Ministry of Health, Abuja, Nigeria.

Raman Velayudha (R)

World Health Organization, Geneva, Switzerland.

Axel Kroeger (A)

Centre for Medicine and Society, University of Freiburg, Freiburg, Germany.

Marcus Panning (M)

Institute of Virologie, Universitatsklinikum, Freiburg, Freiburg, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH